Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80
different histological subtypes. Treatment options remain limited in advanced STS with high …
different histological subtypes. Treatment options remain limited in advanced STS with high …
[HTML][HTML] The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 …
S Pasquali, S Pizzamiglio, N Touati, S Litiere… - European journal of …, 2019 - Elsevier
Background This study was aimed at determining whether patients with high-risk soft tissue
sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant …
sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant …
CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond
F Chibon, T Lesluyes, T Valentin… - Genes, Chromosomes …, 2019 - Wiley Online Library
Prognostication is a key issue for sarcoma patients' care as it triggers the therapeutic
approach including chemotherapy, which is still not standard for localized patients. Current …
approach including chemotherapy, which is still not standard for localized patients. Current …
Self-rectifiable and hypoxia-assisted chemo-photodynamic nanoinhibitor for synergistic cancer therapy
Y Wang, J Huo, S Li, R Huang, D Fan… - … Applied Materials & …, 2022 - ACS Publications
Photodynamic therapy (PDT) can eradicate cancer cells under light irradiation, mainly
because of reactive singlet oxygen (1O2) being transformed from intratumoral oxygen …
because of reactive singlet oxygen (1O2) being transformed from intratumoral oxygen …
[HTML][HTML] Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
F Bertucci, V Niziers, A de Nonneville… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Soft-tissue sarcomas (STSs) are heterogeneous and aggressive tumors, with
high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a …
high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a …
CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study
AM Frezza, S Stacchiotti, F Chibon… - Cancer …, 2023 - Wiley Online Library
Abstract Background The Complexity INdex in SARComas (CINSARC) is a transcriptional
signature derived from the expression of 67 genes involved in mitosis control and …
signature derived from the expression of 67 genes involved in mitosis control and …
[HTML][HTML] The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC
I Acem, WJ van Houdt, DJ Grünhagen… - European Journal of …, 2022 - Elsevier
Objective The aim of the study is to assess the effect of perioperative chemotherapy (CTX) in
patients with grade II-III extremity soft tissue sarcoma (eSTS) on overall survival (OS) and …
patients with grade II-III extremity soft tissue sarcoma (eSTS) on overall survival (OS) and …
[PDF][PDF] Pleomorphic sarcomas: the state of the art
SD Carvalho, D Pissaloux, A Crombé, JM Coindre… - Surgical pathology …, 2019 - Elsevier
This review focuses on pleomorphic sarcomas which are malignant mesenchymal tumors
with highly complex genetic background at the root of their morphological pleomorphism …
with highly complex genetic background at the root of their morphological pleomorphism …
[HTML][HTML] CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II–III colorectal carcinoma
AC Brunac, J Fourquet, G Perot, M Jaffrelot… - Modern Pathology, 2022 - Elsevier
The outcome of stage II–III colorectal cancer (CRC) is highly variable and therapeutic choice
is currently based on TNM staging with a few additional biomarkers. However, studies show …
is currently based on TNM staging with a few additional biomarkers. However, studies show …
The spectrum and significance of secondary (co‐occurring) genetic alterations in sarcomas: the hallmarks of sarcomagenesis
JK Dermawan, BP Rubin - The Journal of Pathology, 2023 - Wiley Online Library
Bone and soft tissue tumors are generally classified into complex karyotype sarcomas
versus those with recurrent genetic alterations, often in the form of gene fusions. In this …
versus those with recurrent genetic alterations, often in the form of gene fusions. In this …